Ignite Creation Date:
2024-10-25 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06646588
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-07
Brief Title:
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Sponsor:
Organization:
None
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
None
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
Time Perspective List:
Who Masked List: